Ravulizumab: a complementary option for PNH

Affiliations

Free article

Comment

Nathan T Connell. Blood. 2019.

Free article

. 2019 Feb 7;133(6):503-504.

doi: 10.1182/blood-2018-12-891499.

No abstract available

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Kulasekararaj AG, et al. Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3. Blood. 2019. PMID: 30510079 Free PMC article. Clinical Trial.
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Lee JW, et al. Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3. Blood. 2019. PMID: 30510080 Free PMC article. Clinical Trial.